Navigation Links
Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Date:4/6/2009

Clinical Force, a web based CTMS (Clinical Trial Management System), has announced that Gemin X Pharmaceuticals has selected and deployed Clinical Force to manage worldwide clinical trials. "We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module" said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

Raleigh, NC (PRWEB) April 6, 2009 -- Clinical Force, the first SaaS, software as a service, CTMS, announces that Gemin X Pharmaceuticals has selected Clinical Force to manage worldwide clinical trials.

As an emerging biotech company working in oncology therapeutics with operations in Montreal Canada and Malvern Pennsylvania, Gemin X Pharmaceuticals selected Clinical Force based on its cost effective monthly subscription fees, adaptable infrastructure requiring no internal IT investment or support, and flexible user interface. In addition, Gemin X expects to improve study efficiencies by requiring their CROs to use Clinical Force on outsourced studies.

"After an extensive review process we felt Clinical Force's modular and cost effective solution met our needs. We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module as well as other innovative functional changes to the system that will lead to process efficiencies and cost savings," said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.

About Clinical Force
Clinical Force delivers a fully functional Clinical Trials Management System (CTMS) to Clinical Research Organizations and Sponsors. Clinical Force is the first company to deliver the CTMS in the Software as a Service (SaaS) model enabling quick installation and a cost effective solution. Organizations in North America, South America, Africa and Europe are successfully using the CTMS to improve internal efficiencies and real time visibility of all studies from an easy to use web based solution. Clinical Force is a privately held company with strong life science pedigree, the company has offices in the US and Europe. www.clinicalforce.com

About Gemin X Pharmaceuticals
Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has several clinical development programs underway, including Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, and preclinical studies for its Telomere Capping and SMAC Mimetic programs. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis.

For more information, please visit www.geminx.com

###

Read the full story at http://www.prweb.com/releases/CTMS/biotechnology/prweb2292394.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
2. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
3. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
4. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
5. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
6. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
8. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
9. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
Breaking Biology News(10 mins):